The ADC targets TROP2 on tumor cells, is internalized, and releases tirumotecan, which inhibits DNA topoisomerase I to cause DNA damage and apoptosis. Topoisomerase I is the intracellular payload target, not the cytotoxic antigen; its expression alone does not trigger targeting or killing.